Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC
Find interim clinical considerations for the use of COVID-19 vaccines for the prevention of coronavirus disease 2019 (COVID-19) in the United States.
volunteer mark this message contains misinformation
｜originally written by volunteer
所謂「白打第一劑」是假訊息，別上當。
目前美國CDC已認可將莫德納或BNT的兩劑間隔時間延長至6週（42天），但美國CDC並沒有說超過6週就會讓第一劑無效，只表示目前對此的研究還不夠多。[見出處1]
此外，目前確實已有相關的科學研究顯示，若將莫德納的兩劑間隔時間延長到至少9週以上，反而是能增加疫苗施打的效力並減少COVID-19的傳播、住院與死亡率。[見出處2]
目前美國CDC已認可將莫德納或BNT的兩劑間隔時間延長至6週（42天），但美國CDC並沒有說超過6週就會讓第一劑無效，只表示目前對此的研究還不夠多。[見出處1]
此外，目前確實已有相關的科學研究顯示，若將莫德納的兩劑間隔時間延長到至少9週以上，反而是能增加疫苗施打的效力並減少COVID-19的傳播、住院與死亡率。[見出處2]
References
[1] https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html[2] https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001211
https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html
https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001211
The content above by Cofacts message reporting chatbot and crowd-sourced fact-checking community is licensed under Creative Commons Attribution-ShareAlike 4.0 (CC BY-SA 4.0), the community name and the provenance link for each item shall be fully cited for further reproduction or redistribution.